The rate of occurrence of FEEHD as estimated by our study in the total cohort is lower (17%) than that in the study which was recently published [16] which was (27.1%), though it is still significantly high in the “at-risk” population (21.9%; patients on hypoglycemia-causing medications such insulin and/or sulfonylureas who had fasting labs). The gene discussed is INS; the disease is Hypoglycemia.